Hester Biosciences Ltd
Pharmaceuticals & Biotechnology | Small Cap
Hester Biosciences Ltd shows a mixed financial performance. The company demonstrates strong growth and profitability, reflected in high scores for growth and profitability ratios. Its solvency is also good, indicating a stable financial structure. However, there are areas of concern, particularly in efficiency and liquidity. The company's efficiency ratios suggest challenges in asset utilization, while liquidity ratios indicate potential difficulties in meeting short-term obligations. The financial ratios also need improvement, reflecting lower earnings per share and higher capital expenditures. While the company shows robust growth and profitability, it needs to address its efficiency and liquidity to ensure long-term financial stability.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio4.40
- Profitability Ratio9.80
- Efficiency Ratio2.67
- Coverage Ratio8.80
- Solvency Ratio8.40
- Liquidity Ratio4.26
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayStrong Bullish
- 1 WeekBullish
- 1 MonthBullish
Hester Biosciences Ltd shows a mixed financial performance. The company demonstrates strong growth and profitability, reflected in high scores for growth and profitability ratios. Its solvency is also good, indicating a stable financial structure. However, there are areas of concern, particularly in efficiency and liquidity. The company's efficiency ratios suggest challenges in asset utilization, while liquidity ratios indicate potential difficulties in meeting short-term obligations. The financial ratios also need improvement, reflecting lower earnings per share and higher capital expenditures. While the company shows robust growth and profitability, it needs to address its efficiency and liquidity to ensure long-term financial stability.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
33.91
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
31.74
P/B RATIO
4.91
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
5.24
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
17.30
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2076.4 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Concall Report⬤2nd Feb 26
Q3 and 9M FY26 Earnings Conference Call
NEUTRAL SENTIMENT
Concall Report⬤12th Nov 25
Q2/H1 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
The growth ratios reflect strong growth across key metrics. High revenue, operating profit, EPS, asset, and net income growth rates demonstrate the company's ability to expand its operations and increase profitability. Sustaining this growth trajectory will be crucial for long-term success and shareholder value creation. The company is performing well in terms of growth and is expected to perform well in future.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 9.81 | 13.19 | 14.66 | 1.97 | 7.07 |
| Operating Profit Growth Rate | -13.04 | -15 | 5.88 | 14.81 | 40.32 |
| Earnings Per Share (EPS) Growth | 14.21 | -32.28 | -29.04 | 45.48 | 102.45 |
| Asset Growth Rate | 36.74 | 19.22 | -1.19 | -1.36 | 3.83 |
| Net Income Growth Rate | 11.43 | -28.21 | -25 | 38.1 | 96.55 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial ratios reveal areas needing improvement. While the dividend per share is good, the adjusted and cash earnings per share, book value per share, and capital expenditures need to be addressed. Enhancing earnings and managing capital expenditures effectively will improve overall financial health and shareholder value, which would benefit the company in the long run.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 43.33 | 32.22 | 25.56 | 33.33 | 63.33 |
| Cash Earnings Per Share (Cash EPS) | 62.22 | 54.44 | 42.22 | 51.11 | 84.44 |
| Book Value Per Share | 288.89 | 311.11 | 324.44 | 350 | 401.11 |
| Dividend Per Share (DPS) | 10.17 | 8.14 | 6 | 7.11 | 11.12 |
| Capital Expenditures (CapEx) | 95.5 | 77.7 | 24.3 | 20.3 | 17.4 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The profitability ratios reflect strong performance across key metrics. High gross profit margin, ROCE, ROE, ROA, operating margin, and net margin demonstrate the company's ability to generate profits efficiently. Sustaining these profitability levels will be crucial for long-term success and shareholder value creation. The company is performing very well in terms of profits.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 18.3 | 11.28 | 12.13 | 14.47 | 20.42 |
| Return on Capital Employed (ROCE) | 14 | 9 | 9 | 10 | 15 |
| Return on Equity (ROE) | 15 | 10 | 7.19 | 9.21 | 15.79 |
| Return on Assets (ROA) | 10.68 | 7.61 | 8.16 | 9.49 | 12.83 |
| Operating Margin | 25.53 | 19.17 | 17.7 | 19.94 | 26.13 |
| Net Margin | 16.6 | 10.53 | 6.89 | 9.32 | 17.12 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The efficiency ratios reveal challenges in asset utilization. Low turnover ratios and high days sales in inventory and receivable days suggest inefficiencies in managing assets and working capital. While the company is collecting its receivables in an average time, the turnover ratios need improvement. Addressing these inefficiencies will enhance overall operational performance and profitability.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 0.99 | 1.03 | 1.27 | 1.33 | 0.79 |
| Inventory Turnover Ratio | 2.8 | 2.95 | 3.33 | 3.66 | 3.71 |
| Receivables Turnover Ratio | 4.52 | 3.94 | 3.84 | 4.09 | 3.96 |
| Days Sales in Inventory Ratio | 130.36 | 123.73 | 109.61 | 99.73 | 98.38 |
| Receivable Days | 80.75 | 92.64 | 95.05 | 89.24 | 92.17 |
| Capital Turnover Ratio | 0.55 | 0.56 | 0.64 | 0.69 | 0.73 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The coverage ratios reflect a strong ability to meet interest and dividend obligations. The interest coverage ratio indicates a comfortable margin for covering interest expenses, while the equity dividend coverage ratio suggests a solid capacity to pay dividends. Maintaining these coverage levels supports financial stability and investor confidence. As a result the company is able to pay off debts and give dividends.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 14.5 | 5.44 | 2.6 | 4.08 | 7.91 |
| Equity Dividend Coverage Ratio | 4.55 | 3.85 | 3.7 | 4.55 | 5.88 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The solvency position is strong, indicating a stable financial structure. The debt, debt-to-equity, and equity ratios reflect a balanced approach to financing, with a healthy reliance on equity. The debt-to-asset ratio further confirms effective asset management and low financial risk. Maintaining this balance will support long-term financial health and stability.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.4 | 0.41 | 0.39 | 0.3 | 0.21 |
| Debt to Equity Ratio | 0.67 | 0.69 | 0.64 | 0.43 | 0.27 |
| Equity Ratio | 0.6 | 0.59 | 0.61 | 0.7 | 0.79 |
| Debt To Asset Ratio | 0.3 | 0.29 | 0.28 | 0.21 | 0.14 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The liquidity position reveals challenges in meeting short-term obligations. The current and operating cash flow ratios suggest potential difficulties in covering current liabilities. While the quick ratio is average, the low cash ratio indicates limited immediate liquidity. This situation could strain the company's ability to handle unforeseen expenses or invest in growth opportunities. On the other hand, an average quick ratio indicates the business is able to pay its immediate liabilities.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.68 | 1.19 | 1.21 | 1.01 | 0.97 |
| Quick Ratio | 1.11 | 0.76 | 0.79 | 0.67 | 0.64 |
| Cash Ratio | 0.19 | 0.08 | 0.08 | 0.04 | 0.03 |
| Operating Cash Flow Ratio | 0.07 | 0.12 | 0.26 | 0.33 | 0.29 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 33.01 | Overvalued | 58.00 | 6.42 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 4 | Windlas Biotech Ltd | 7.52 | 25.92 | Neutral | 105.00 | 32.19 | 66.00 |
| 5 | Lincoln Pharmaceuticals Ltd | 7.31 | 14.01 | Neutral | 98.00 | 43.88 | 88.00 |
| 6 | NGL Fine Chem Ltd | 6.98 | 39.22 | Overvalued | 73.00 | 67.39 | 48.00 |
| 7 | Syncom Formulations (India) Ltd | 6.92 | 17.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 8 | Kilitch Drugs (India) Ltd | 6.61 | 21.54 | Neutral | 37.00 | 9.27 | 30.00 |
| 9 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 10 | Hester Biosciences Ltd | 6.54 | 31.74 | Neutral | 87.00 | 61.24 | 57.00 |
| 11 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 12 | Sakar Healthcare Ltd | 5.81 | 58.66 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 13 | Medicamen Biotech Ltd | 5.73 | 32.19 | Neutral | 20.00 | 6.94 | 10.00 |
| 14 | Remus Pharmaceuticals Ltd | 5.31 | 25.48 | Neutral | 57.00 | 20.97 | 46.00 |
| 15 | Ind-Swift Laboratories Ltd | 4.95 | 39.28 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 17 | Wanbury Ltd | 4.65 | 28.62 | Neutral | 88.00 | 18.93 | 43.00 |
| 18 | Solara Active Pharma Sciences Ltd | 4.34 | -274.68 | Neutral | 187.00 | -1.50 | -7.00 |
Hester Biosciences exhibits a mixed performance profile, suggesting moderate management effectiveness. Sales growth shows a positive trend over the years, but profit growth has been inconsistent. The company maintains moderate capital efficiency with fluctuating ROCE and ROE. Financial health is marked by increasing debt. Recent quarterly results show volatile profit growth, impacting overall stability. Promoter holding remains strong, indicating confidence. Overall, management demonstrates strengths in sales and promoter confidence but faces challenges in sustaining profit growth and managing debt effectively.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Compounded Sales Growth (10Y) | 13% | Strong revenue expansion |
| Promoter Holding | 53.73% | High promoter confidence | |
| CONS | Compounded Profit Growth (5Y) | -1% | Weak profit growth |
| Debt/Equity Ratio (Recent) | Increased Borrowings | Increasing leverage |
Financial Performance & Growth
Hester Biosciences demonstrates a mixed performance in financial growth. While sales have shown consistent expansion, profit growth has been volatile and recently declining. The compounded sales growth over 10 years is strong at 13%, indicating a positive long-term trend. However, the compounded profit growth over 5 years is -1%, and over 3 years is -11%, suggesting challenges in maintaining profitability. Quarterly results show fluctuations in sales and profit growth, with recent YOY profit growth varying widely. OPM has seen fluctuations, with a recent dip in Dec 2024. This inconsistent profit performance raises concerns about the sustainability of growth.
| Metric | 2015-2017 | 2018-2020 | 2021-2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Sales Growth (%) | 21.69% | 17.62% | 12.96% | 14.45% | 2.15% |
| Profit Growth (%) | 16.67% | 10.11% | -1.33% | -24.00% | 38.10% |
Capital Efficiency & Returns
The capital efficiency and returns for Hester Biosciences present a mixed picture. ROCE has declined, indicating potentially less effective capital utilization. ROE is moderate but has also decreased, suggesting lower returns on shareholder funds. Cash conversion cycle data shows fluctuations, indicating variability in working capital management efficiency.ROCE % has declined over the years.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE (%) | 17% | 22% | 15% | 9% | 9% | 10% |
Financial Health & Prudence
Hester Biosciences exhibits concerns regarding financial health and prudence. Debt levels have increased, raising concerns about financial leverage. The dividend payout ratio is consistent, indicating a commitment to sharing profits. The increasing borrowings suggest potential financial strain, requiring careful monitoring.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Borrowings | 55 Cr | 77 Cr | 185 Cr | 274 Cr | 244 Cr | 213 Cr |
Strategic & Operational Indicators
The strategic and operational indicators provide limited insights. The working capital management is somewhat inefficient. Fixed asset management shows a strategic approach to asset investment, but detailed analysis is constrained by data availability.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 81 Days | 78 Days | 92 Days | 109 Days | 94 Days | 86 Days |
Hester Biosciences demonstrates moderate risk. The company's increasing debt levels pose a financial risk, although consistent dividend payouts provide some stability. A high promoter holding indicates confidence, but declining ROCE and ROE raise concerns about capital efficiency.Overall, the company exhibits financial and operational risks that warrant monitoring.
Contingent liability evaluation
There is no specific data available on contingent liability evaluation. Without this information, it is not possible to determine the potential impact of uncertain future events on the company's financial stability.
Foreign exchange or interest rate exposure
The company's increasing debt levels expose it to interest rate risk, as higher rates could increase borrowing costs and impact profitability. There is no available data to evaluate Foreign exchange exposure for the company.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102063.14Bullish
- SMA 202062.08Bullish
- SMA 502027.15Bullish
- EMA 102062.17Bullish
- EMA 202058.02Bullish
- EMA 502034.51Bullish
- DEMA 102064.31Bullish
- DEMA 202070.19Bullish
- DEMA 502070.50Bullish
- TEMA 102064.63Bullish
- TEMA 202063.31Bullish
- TEMA 502076.97Bullish
- MACD8.03Bearish
- ADX35.55Strong Trend
- IndicatorValueSignal
- RSI57.92Neutral
- CCI118.78Overbought
- ROC 90.94Bullish
- ROC 142.32Bullish
- ROC 252.15Bullish
- Stoch K38.01Neutral
- Stoch D24.92Neutral
- IndicatorValueSignal
- BB Upper2096.70Neutral
- BB Middle2062.08Neutral
- BB Lower2027.46Neutral
- ATR36.38High Volatility
- IndicatorValueSignal
- MFI67.50Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102062.67Bullish
- SMA 202062.74Bullish
- SMA 501997.95Bullish
- EMA 102063.73Bullish
- EMA 202049.44Bullish
- EMA 502010.32Bullish
- DEMA 102074.10Bullish
- DEMA 202077.93Bullish
- DEMA 502072.91Bullish
- TEMA 102070.12Bullish
- TEMA 202080.61Bullish
- TEMA 502065.18Bullish
- MACD20.46Bearish
- ADX35.52Strong Trend
- IndicatorValueSignal
- RSI58.28Neutral
- CCI135.25Overbought
- ROC 91.47Bullish
- ROC 142.59Bullish
- ROC 257.04Bullish
- Stoch K34.18Neutral
- Stoch D36.60Neutral
- IndicatorValueSignal
- BB Upper2095.52Neutral
- BB Middle2062.74Neutral
- BB Lower2029.96Neutral
- ATR47.88Low Volatility
- IndicatorValueSignal
- MFI69.36Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102063.27Bullish
- SMA 202007.87Bullish
- SMA 501962.54Bullish
- EMA 102049.88Bullish
- EMA 202022.76Bullish
- EMA 501939.24Bullish
- DEMA 102077.35Bullish
- DEMA 202070.51Bullish
- DEMA 502089.40Bearish
- TEMA 102079.51Bullish
- TEMA 202071.12Bullish
- TEMA 50N/AN/A
- MACD36.40Bullish
- ADX45.06Strong Trend
- IndicatorValueSignal
- RSI59.28Neutral
- CCI79.45Neutral
- ROC 91.05Bullish
- ROC 146.74Bullish
- ROC 257.22Bullish
- Stoch K63.96Neutral
- Stoch D64.83Neutral
- IndicatorValueSignal
- BB Upper2124.97Neutral
- BB Middle2007.87Neutral
- BB Lower1890.77Neutral
- ATR68.11High Volatility
- IndicatorValueSignal
- MFI63.09Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102006.63Bullish
- SMA 201993.26Bullish
- SMA 501767.69Bullish
- SMA 1001620.75Bullish
- SMA 2001675.54Bullish
- EMA 102021.69Bullish
- EMA 201967.86Bullish
- EMA 501821.14Bullish
- EMA 1001720.83Bullish
- EMA 2001709.14Bullish
- DEMA 102067.56Bullish
- DEMA 202076.35Bullish
- DEMA 501997.70Bullish
- DEMA 1001809.86Bullish
- DEMA 2001656.68Bullish
- TEMA 102069.32Bullish
- TEMA 202071.12Bullish
- TEMA 502101.68Bearish
- TEMA 1001952.20Bullish
- TEMA 2001713.77Bullish
- MACD77.92Bearish
- ADX63.72Strong Trend
- IndicatorValueSignal
- RSI67.12Neutral
- CCI89.74Neutral
- ROC 142.94Bullish
- ROC 2519.32Bullish
- Stoch K69.80Neutral
- Stoch D65.18Neutral
- IndicatorValueSignal
- BB Upper2128.85Neutral
- BB Middle1993.26Neutral
- BB Lower1857.67Neutral
- ATR94.60Low Volatility
- IndicatorValueSignal
- MFI57.51Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 201603.78Bullish
- SMA 501706.22Bullish
- EMA 201693.05Bullish
- EMA 501703.33Bullish
- DEMA 201769.87Bullish
- DEMA 501614.27Bullish
- TEMA 201894.45Bullish
- TEMA 501624.70Bullish
- MACD77.46Bullish
- ADX29.14Strong Trend
- IndicatorValueSignal
- RSI60.09Neutral
- CCI85.79Neutral
- ROC 1432.48Bullish
- ROC 2523.14Bullish
- Stoch K73.57Neutral
- Stoch D77.26Neutral
- IndicatorValueSignal
- BB Upper2011.01Neutral
- BB Middle1603.77Neutral
- BB Lower1196.54Neutral
- ATR154.50Low Volatility
- IndicatorValueSignal
- MFI82.71Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 61591.35Bullish
- SMA 121712.79Bullish
- SMA 241938.54Bullish
- EMA 61684.66Bullish
- EMA 121705.50Bullish
- EMA 241777.47Bullish
- DEMA 61718.73Bullish
- DEMA 121625.93Bullish
- DEMA 241678.30Bullish
- TEMA 61811.94Bullish
- TEMA 121634.43Bullish
- TEMA 241607.42Bullish
- MACD-50.17Bearish
- ADX16.77Weak Trend
- IndicatorValueSignal
- RSI51.95Neutral
- CCI13.79Neutral
- ROC 2522.12Bullish
- ROC 50-25.95Bearish
- Stoch K23.59Neutral
- Stoch D31.98Neutral
- IndicatorValueSignal
- BB Upper2505.79Neutral
- BB Middle1809.40Neutral
- BB Lower1113.00Neutral
- ATR377.36High Volatility
- IndicatorValueSignal
- MFI83.84Overbought